![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, July 23, 2018 9:42:00 PM
To my eye there's some problems with that complaint. One is that, in 2014 and up to today, a $2 or $3 or $4/share valuation of IPIX's pipeline is quite reasonable in the biotech landscape. The science and possible revenue streams for IPIX are broad and have had zero rebuttals from the ultimate arbiter, the FDA. The potential benefiting patient base for IPIX's three (3!) candidates is in the 100's of millions. Biotech competitors regularly receive compelling sums for thinly-tested drug assets that are dubious or have a miniscule target population. Leo had then (and continues to have) reason to expect that a SP valuation at least in the high single digits was close at hand. He was in no hurry to dilute the stock. And then some bad press tornadoes came, along with market indifference. The shark bite took out a good hunk of flesh.
Related, I believe that Leo absolutely detests diluting the stock. Diluting his stock. He sold really cheap shares to Aspire with gritted teeth recently, cut costs wherever he could including the aging Menon's salary, and a penny-pinching CEO is usually a shareholder's friend, non? Does he draw a good salary himself? Yes. Will he buy St. Lucia with his salary and spend his days and shareholder cash getting coconut oil rubdowns three times daily under the palms lighting cigars with Franklins? That's absurd. Leo didn't sell shares at $2 or $4 because he didn't think he had to. I didn't think he had to either.
Should I have sold all my IPIX shares in 2014 at $4.50 and hung around until mid-2018 and plunked the whole stash down again and own a whole bunch more shares? Of course. Am I a backwoods rube because I didn't do this? No. But then again I may lack the investing IQ of a typical cellophane-wrapped honey Bun.
The beauty and 20/20 blindness of hindsight.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM